24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
CRIZLIEVA 250MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | CRIZLIEVA 250MG |
|---|---|
| Composition | Crizotinib Tablets 250mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (60Tab) |
| Country of Origin | India |
CRIZLIEVA 250MG (Crizotinib Tablets 250mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
CRIZLIEVA 250 MG (Crizotinib Tablets 250 mg) is a prescription targeted anticancer medicine containing Crizotinib 250 mg, used for the treatment of specific types of advanced and metastatic cancers that carry certain genetic abnormalities. Crizotinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs) and is designed to block abnormal proteins that drive cancer cell growth, survival, and spread.
Cancer develops when cells acquire genetic mutations that allow them to multiply uncontrollably. In some patients with Non-Small Cell Lung Cancer (NSCLC) and other rare cancers, abnormal changes in genes such as ALK (Anaplastic Lymphoma Kinase), ROS1, or MET can stimulate continuous cancer cell growth. CRIZLIEVA 250 MG specifically targets these abnormal signaling pathways, helping slow disease progression and improve treatment outcomes.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Crizotinib is a targeted therapy that focuses on specific cancer-driving mutations. This targeted approach allows for more precise treatment and has become an important option in modern oncology.
CRIZLIEVA 250 MG is commonly prescribed for:
Before starting treatment, doctors often perform specialized molecular testing to identify whether the patient's cancer carries the genetic alterations that make Crizotinib an appropriate treatment option.
Manufactured under stringent pharmaceutical quality standards, CRIZLIEVA 250 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Crizotinib therapy require regular medical monitoring, including blood tests, liver function assessments, vision evaluations, heart monitoring, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical benefits and targeted mechanism of action, CRIZLIEVA 250 MG remains an important treatment option in modern precision oncology worldwide.
CRIZLIEVA 250 MG (Crizotinib Tablets 250 mg) is primarily used for the treatment and management of cancers associated with specific genetic mutations.
The medicine is widely used in patients whose lung cancer carries ALK gene rearrangements.
Crizotinib may be prescribed for patients with ROS1-positive metastatic lung cancer.
The medicine helps manage advanced-stage lung cancers driven by targetable mutations.
It may be used when cancer has spread to other parts of the body.
Doctors may prescribe Crizotinib based on molecular diagnostic testing results.
The medicine helps control disease progression and maintain treatment response.
Crizotinib is often included in modern personalized cancer treatment plans.
Crizotinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
CRIZLIEVA works by:
This targeted action helps slow the growth of cancer cells while minimizing damage to healthy tissues.
Like all medicines, CRIZLIEVA 250 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual response.
Patients may experience mild to moderate nausea.
Some individuals may develop vomiting during treatment.
Digestive disturbances and loose stools may occur.
Certain patients may experience constipation.
Weakness and tiredness are commonly reported.
Blurred vision, light sensitivity, or visual changes may occur.
Fluid retention and mild swelling may develop.
Reduced appetite may affect nutritional intake.
The medicine may affect liver function and require regular monitoring.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of CRIZLIEVA 250 MG (Crizotinib Tablets 250 mg) should always be determined by a qualified oncologist.
Treatment plans vary according to the diagnosed cancer and genetic profile.
Overall health and medical history influence dosage decisions.
Liver health may affect treatment planning and dose adjustments.
Doctors may modify dosage according to effectiveness and tolerability.
Certain medicines may interact with Crizotinib and require dosage modifications.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, over-the-counter drugs, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for ALK-positive and ROS1-positive Non-Small Cell Lung Cancer (NSCLC) and certain other cancers with specific genetic mutations.
Crizotinib is a targeted anticancer medicine that blocks abnormal proteins responsible for cancer cell growth and survival.
No. It is a targeted therapy that works differently from traditional chemotherapy medicines.
Genetic testing helps determine whether the cancer contains specific mutations such as ALK or ROS1 that are likely to respond to Crizotinib.
Yes, some patients may experience visual disturbances during treatment, which should be reported to a healthcare provider.
Yes, routine blood tests, liver assessments, and medical evaluations are important throughout therapy.
Treatment duration depends on disease response, patient tolerance, and the oncologist's recommendations.
Yes, this medicine should only be used under the guidance of qualified healthcare professionals experienced in oncology and targeted cancer therapy.